

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims**

Claims 1-4. (Canceled)

Claim 5. (Currently Amended). The peptide according to claim 16 ~~4~~ which has the formula:  
NH<sub>2</sub>-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-Phe-OH (SEQ ID NO. 6),  
NH<sub>2</sub>-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-OH (SEQ ID NO. 7),  
NH<sub>2</sub>-Leu-Arg-Ile-Leu-Leu-Leu-Gly-Val-OH (SEQ ID NO. 8),  
NH<sub>2</sub>-Leu-Gly-Ile-Leu-Leu-Leu-Lys-Val-OH (SEQ ID NO. 9),  
NH<sub>2</sub>-Ile-Leu-Leu-Gly-Lys-Ala-Thr-Leu-Tyr-OH (SEQ ID NO. 10),  
NH<sub>2</sub>-Met-Gly-Leu-Arg-Ile-Leu-Leu-Leu-OH (SEQ ID NO. 11), or  
NH<sub>2</sub>-Leu-Leu-Met-Thr-Leu-Arg-Leu-Trp-Ser-Ser-COOH (SEQ ID NO. 12).

Claim 6. (Canceled)

Claim 7. (Currently Amended) A peptide ~~according to claim 6~~ which inhibits TCR function, wherein the peptide has the formula  
NH<sub>2</sub>-Ile-Ile-Val-Thr-Asp-Val-Ile-Ala-Thr-Leu-OH (SEQ ID NO. 13),  
NH<sub>2</sub>-Ile-Val-Ile-Val-Asp-Ile-Cys-Ile-Thr-OH (SEQ ID NO. 14), or  
NH<sub>2</sub>-Phe-Leu-Phe-Ala-Glu-Ile-Val-Ser-Ile-OH (SEQ ID NO. 15).

Claim 8. (Previously Presented) A peptide which inhibits TCR function, wherein the peptide is derived from the TCR- $\alpha$  intracellular chain and comprises the formula:

NH<sub>2</sub>-Ala-Gly-Phe-Asn-Leu-Leu-Met-Thr-COOH (SEQ ID NO. 16).

Claims 9-11. (Canceled)

- Claim 12. (Previously Presented) A peptide which inhibits T-Cell antigen receptor function wherein the peptide has the formula:
- NH<sub>2</sub>-Tyr-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 17), or  
NH<sub>2</sub>-Trp-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 18), or  
NH<sub>2</sub>-Tyr-Gly-Arg-Ala-Asp-Cys-Ile-Thr-Ser-OH (SEQ ID NO. 19), or  
NH<sub>2</sub>-Ser-Ser-Asp-Val-Pro-Cys-Asp-Ala-Thr-Leu-Thr-OH (SEQ ID NO. 20).
- Claim 13. (Currently amended) A therapeutic composition active against disorders in which T-cells are involved or recruited comprising a peptide as claimed in claim ~~48~~ 16, and a pharmaceutically acceptable carrier.
- Claim 14. (Currently amended) A method of treating a subject suffering from a disorder in which T-cells are involved or recruited, the method including administering to the subject a therapeutically effective amount of the composition as claimed in claim ~~44~~ 13.
- Claim 15. (Canceled)
- Claim 16. (New) A peptide that inhibits T-cell antigen receptor (TCR) function, which has a formula selected from the group consisting of formula
- NH<sub>2</sub>-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-Phe-OH (SEQ ID NO. 6),  
NH<sub>2</sub>-Ile-Leu-Leu-Leu-Lys-Val-Ala-Gly-OH (SEQ ID NO. 7),  
NH<sub>2</sub>-Leu-Arg-Ile-Leu-Leu-Leu-Gly-Val-OH (SEQ ID NO. 8),  
NH<sub>2</sub>-Leu-Gly-Ile-Leu-Leu-Leu-Lys-Val-OH (SEQ ID NO. 9),  
NH<sub>2</sub>-Ile-Leu-Leu-Gly-Lys-Ala-Thr-Leu-Tyr-OH (SEQ ID NO. 10),  
NH<sub>2</sub>-Met-Gly-Leu-Arg-Ile-Leu-Leu-Leu-OH (SEQ ID NO. 11),  
NH<sub>2</sub>-Leu-Leu-Met-Thr-Leu-Arg-Leu-Trp-Ser-Ser-COOH (SEQ ID NO. 12)  
NH<sub>2</sub>-Ile-Ile-Val-Thr-Asp-Val-Ile-Ala-Thr-Leu-OH (SEQ ID NO. 13)  
NH<sub>2</sub>-Ile-Val-Ile-Val-Asp-Ile-Cys-Ile-Thr-OH (SEQ ID NO. 14),  
NH<sub>2</sub>-Phe-Leu-Phe-Ala-Glu-Ile-Val-Ser-Ile-OH (SEQ ID NO. 15)

NH<sub>2</sub>-Ala-Gly-Phe-Asn-Leu-Leu-Met-Thr-COOH (SEQ ID NO. 16).

NH<sub>2</sub>-Tyr-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 17),

NH<sub>2</sub>-Trp-Gly-Arg-Ala-Asp-Cys-Gly-Ile-Thr-Ser-OH (SEQ ID NO. 18),

NH<sub>2</sub>-Tyr-Gly-Arg-Ala-Asp-Cys-Ile-Thr-Ser-OH (SEQ ID NO. 19), or

NH<sub>2</sub>-Ser-Ser-Asp-Val-Pro-Cys-Asp-Ala-Thr-Leu-Thr-OH (SEQ ID NO. 20).